Aduro Biotech, Inc. (ADRO)
(Delayed Data from NSDQ)
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.26 USD
+0.11 (2.65%)
Updated May 3, 2019 04:00 PM ET
After-Market: $4.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Is a Beat in Store for WellCare Health's (WCG) Q1 Earnings?
by Zacks Equity Research
WellCare Health's (WCG) first-quarter earnings are likely to gain from a rise in membership, partly offset by high debt load.
Tenet Healthcare (THC) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Tenet Healthcare (THC) is likely to be hit by declining revenues in the first quarter of 2019.
Is a Beat in Store for Editas (EDIT) This Earnings Season?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus will be on the company's progress with its most advanced pipeline candidate, EDIT-101.
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Incyte, Aduro Biotech, MeiraGTx and Coherus BioSciences
What's in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
On Vertex's (VRTX) first-quarter earnings call, investor focus will be on its latest CF drug Symdeko's sales figure as well as the update on its CF triple-pill regimes.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
by Zacks Equity Research
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.
Anthem's (ANTM) Q1 Earnings Beat Estimates, Improve Y/Y
by Zacks Equity Research
Anthem's (ANTM) Q1 earnings surge on the back of a solid operating performance and strong growth across all core businesses.
Aduro Biotech (ADRO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Aduro Biotech (ADRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Biotech Stocks Defying the Medicare-for-All Scare
by Swarup Gupta
Unlike the broader healthcare sector, biotech stocks have notched up strong gains year to date.
Exact Sciences (EXAS) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
During Exact Sciences' (EXAS) first-quarter 2019 conference call, investor focus will be on the growth rate in the company's non-invasive screening test volume for colorectal cancer, Cologuard.
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
by Zacks Equity Research
Strong growth of Imbruvica and Mavyret are expected to drive AbbVie (ABBV) first-quarter sales. Declining ex-U.S. Humira sales are likely to be an overhang on the top line.
Why Is Aduro Biotech (ADRO) Down 10.7% Since Last Earnings Report?
by Zacks Equity Research
Aduro Biotech (ADRO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Lilly (LLY) Signs New Immunology Deal With Private Biotech
by Zacks Equity Research
Eli Lilly (LLY) gets an exclusive, worldwide license to develop and commercialize a novel immunometabolism target from private biotech, ImmuNext.
The Meet Group (MEET) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
The Meet Group's (MEET) fourth-quarter 2018 results are expected to benefit from strong growth in video revenues.
Aduro (ADRO) Q4 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Wider-than-expected loss affects Aduro (ADRO) in the fourth quarter. Also, revenues lag estimates.
Top Ranked Momentum Stocks to Buy for February 28th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 28th:
Top Ranked Momentum Stocks to Buy for February 27th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 27th:
Will Aduro Biotech Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aduro Biotech.
What's in Store for Universal Health (UHS) Q4 Earnings?
by Zacks Equity Research
Universal Health's (UHS) earnings in the fourth quarter are likely to gain from higher admissions and patient days.
Top Ranked Momentum Stocks to Buy for February 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, February 25th:
What's in Store for Vericel (VCEL) This Earnings Season?
by Zacks Equity Research
On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
by Zacks Equity Research
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
by Zacks Equity Research
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
What's in Store for Tandem Diabetes' (TNDM) Q4 Earnings?
by Zacks Equity Research
Strong domestic sales along with the launch of the t:slim X2 Insulin Pump in select international markets are likely to drive Tandem Diabetes' (TNDM) Q4 earnings.